Resolian Malvern USA Bioanalytical Lab Tour
Take a virtual tour of Resolian’s Malvern bioanalytical laboratory – where our expert scientists deliver high-quality data to support nonclinical and clinical trials.
Take a virtual tour of Resolian’s Malvern bioanalytical laboratory – where our expert scientists deliver high-quality data to support nonclinical and clinical trials.
Did you know that you can start Phase I trials in Australia without an IND? That’s just one of several strategic benefits biotechs are leveraging to speed up development timelines and reduce costs – while generating globally accepted data.
In this article, we break it down.
What would you do if you found a piece of unidentified material in your toothpaste today? Would you use it? Would you throw the whole tube away? Or, would you send a complaint to the company..?
Foreign matter is an issue across all industries – from food to medicines and consumer products
At Resolian we specialise in the efficient development of highly selective, tailored methods which differentiate between nitrosamines and structurally similar impurities that would otherwise lead to a false positive.
🔬 How do you measure complex modality molecules at the lowest possible concentrations?
For modern therapies like antibody-drug conjugates (ADCs) and inhzlation drugs, precise bioanalysis at picogram levels is essential to ensure both efficacy and safety. At Resolian, we specialize in ultrasensitive assays that push the boundaries of detection.
Precision, efficiency, and scientific expertise are essential in today’s fast-moving bioanalytical landscape. At Resolian, we’ve taken a bold step forward—restructuring teams, refining method development processes, and strategically implementing automation to enhance service delivery.
Polymorph screening is a process that identifies and characterizes the crystalline forms of a compound, and then selects the best form for development.
Assessing and controlling the crystalline form of your material plays a crucial role in all the stages of the product lifecycle.
Explore our UK labs in these site tours.
The staff may have changed but the capabilities remain.
Foreign particulate matter (FPM) in vaccines poses risks to product safety, patient health, and regulatory compliance. With stringent guidelines from agencies like the FDA and EMA, identifying and controlling contaminants is essential to maintaining trust and ensuring safety.
Min Meng, Chief Operations Officer at Resolian. The interview focuses on the bioanalysis of oligonucleotide therapeutics, a rapidly evolving area in drug development. Min Meng, with 20+ years of experience in this field, provides valuable insights into the unique challenges and advantages of these therapies.